Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone Effect on GFR Autoregulation in T1D
NCT00335413Phase 4Completed
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Jun 2006
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in hypertension (HTN) comparing Spironolactone with Placebo (2 arms). Primary endpoint: Changes in glomerular filtration rate at 28 days. Started Jun 2006; status: completed.
02
Drugs
spironolactone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00335413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00335413.